A large clinical trial has confirmed that semaglutide meaningfully reduces the risk of serious heart events in people living with obesity and cardiovascular disease — yet science cannot fully account for why. When researchers traced the drug's protective effect back through known biological pathways, only a third of the benefit could be explained, leaving medicine in the unusual position of knowing that something works without knowing how. It is a reminder that the human body often outruns the frameworks we build to understand it.
Semaglutide's heart benefits remain partially mysterious despite 20% event reduction
The remaining two-thirds remains a mystery.
Mark
So semaglutide cuts heart events by 20 percent, but only about a third of that benefit comes from the things we can measure—weight loss, blood pressure, cholesterol. What does that actually mean for how we should think about the drug?
Mimi
It means the drug is doing something we don't yet understand. We can see the outcome—fewer heart attacks and strokes—but when we trace the path from the drug to that outcome through the factors we know how to measure, we only account for about a third of the journey. The other two-thirds is still in the dark.
Luke
But I want to be careful here. The mediation estimate is 31.4 percent, but the statistical uncertainty was large enough that the researchers couldn't call that number precise. We're not saying with confidence that exactly 31 percent is explained. We're saying somewhere in that range, with a wide margin of error.
Mark
Right. So when they say 69 percent is unexplained, that's not a hard number either.
Mimi
Correct. It's a point estimate with substantial uncertainty around it. The researchers are being honest about that limitation. They're not claiming to have solved the puzzle; they're saying the puzzle is bigger than we thought.
Luke
And the individual mediation estimates are even more uncertain. Waist circumference alone showed 64 percent mediation when looked at by itself, but that number came with its own statistical fog. Some of those estimates may have been distorted by weight loss in placebo participants who were getting sicker, not healthier.
Mark
So what are the actual candidates for what's happening in that missing two-thirds?
Mimi
The researchers propose vascular effects, changes to plaque, liver inflammation, epicardial fat, circulating proteins. But they're careful to call these speculative. They haven't measured them. They're educated guesses about where to look next.
Luke
And that's important to name. We know semaglutide reduces heart events. We don't know why. The study doesn't answer that question; it clarifies how much of the answer we're still missing.
Mark
Does this change how doctors should prescribe the drug?
Mimi
Not immediately. The clinical benefit is real and measured. But it does suggest that the benefit might be more robust than we'd expect from weight loss alone, which could matter for how we counsel patients or design future treatments.
The Pulse
- A 20% reduction in heart attacks, strokes, and cardiovascular deaths was confirmed across 17,604 patients — a result too large to dismiss and too mysterious to fully explain.
- When scientists mapped the benefit against every measurable risk factor — weight, blood pressure, cholesterol, glucose, inflammation — the numbers accounted for barely a third of the drug's protection.
- The gap has unsettled researchers: vascular changes, plaque behavior, liver inflammation, and cardiac fat are now being proposed as possible hidden engines of the drug's effect, though none has been proven.
- Statistical limitations, missing data, and the complexity of combining twelve biological mediators into one model mean the 31% figure itself carries significant uncertainty.
- The field now faces a clear research imperative — to measure what has not yet been measured — while clinicians must act on a drug they know protects the heart through mechanisms that remain partially in the dark.
A large clinical trial has confirmed that semaglutide meaningfully reduces the risk of serious heart events in people living with obesity and cardiovascular disease — yet science cannot fully account for why. When researchers traced the drug's protective effect back through known biological pathways, only a third of the benefit could be explained, leaving medicine in the unusual position of knowing that something works without knowing how. It is a reminder that the human body often outruns the frameworks we build to understand it.
Semaglutide reduces the risk of major heart events by roughly a fifth in people with obesity and established cardiovascular disease — one of the more striking findings to emerge from a large-scale drug trial in recent years. But a new statistical examination of that trial has revealed something deeply puzzling: the protection cannot be adequately explained by the biological factors medicine has long associated with heart disease.
The SELECT trial enrolled 17,604 adults and followed them for nearly 40 months. Those receiving weekly semaglutide injections saw major cardiovascular events fall from 8.0% to 6.5% compared to placebo. To understand how the drug produced this effect, researchers applied a method called counterfactual mediation modeling, tracing the benefit through twelve measurable factors — weight, waist circumference, blood pressure, cholesterol, blood glucose, kidney markers, and inflammation. Together, these explained only about 31% of the drug's protective effect.
Examined individually, waist circumference showed the strongest link, followed by an inflammation marker and blood glucose. Body weight alone accounted for less than 20%. But when all factors were combined, the joint estimate settled at 31.4%, leaving nearly 70% of the benefit without a clear biological home.
The researchers, publishing in the European Heart Journal, are candid about what this means: semaglutide appears to be working through pathways that current science has not yet identified. They propose possibilities — effects on arterial function, changes in atherosclerotic plaque, reductions in liver or cardiac fat, shifts in circulating proteins — but are careful to call these speculations rather than conclusions.
The study's limitations are real. Statistical uncertainty around many estimates was substantial, and sensitivity analyses suggested that weight-loss figures may have been skewed by illness-related weight loss among placebo participants. Missing data further constrained what could be definitively shown.
What remains is a portrait of a drug that outperforms the explanatory frameworks built around it. Semaglutide was developed for diabetes, proved effective for weight loss, and has now demonstrated cardiovascular protection even in people without diabetes — protection that persists even after accounting for the weight loss itself. The drug works. The full reason why is still being written.
Semaglutide cuts the risk of major heart events by a fifth in people with obesity and established cardiovascular disease—a finding that has emerged from one of the largest drug trials in recent years. Yet the mechanism behind this protection remains stubbornly opaque. Researchers have now conducted a detailed statistical examination of the SELECT trial, which enrolled 17,604 adults over an average of nearly 40 months, and they have discovered something unsettling: the cardiovascular benefits cannot be fully explained by the factors doctors have long believed drive heart disease.
The original SELECT trial showed that weekly injections of semaglutide at a target dose of 2.4 milligrams reduced major adverse cardiovascular events—defined as cardiovascular death, heart attack, or stroke—from 8.0 percent in the placebo group to 6.5 percent in those receiving the drug. That 20 percent reduction is substantial. But when researchers applied a statistical method called counterfactual mediation modeling to the trial data, they found that traditional risk factors could account for only about 31 percent of this benefit. Weight loss, waist circumference, blood pressure, cholesterol, blood glucose, and inflammation markers together explained roughly one-third of the drug's protective effect. The remaining two-thirds remains a mystery.
The analysis examined twelve candidate mediators—measurable factors that might explain how the drug works. Changes in waist circumference produced the largest estimated mediation at 64 percent when examined individually, followed by high-sensitivity C-reactive protein at 42 percent and blood glucose at 29 percent. Body weight alone accounted for only 19.5 percent. Other measures including triglycerides, kidney function markers, and cholesterol fractions each contributed smaller pieces. But when researchers combined all these factors into a single multivariable model, the joint mediation estimate settled at 31.4 percent—leaving a substantial gap between what is measured and what is observed.
This gap matters because it suggests that semaglutide is working through biological pathways that current medical science has not yet identified or measured. The researchers acknowledge this plainly in their conclusions, published in the European Heart Journal. They propose several speculative possibilities: effects on vascular function, changes to atherosclerotic plaque itself, reduction of liver inflammation, alterations in epicardial fat surrounding the heart, or shifts in circulating proteins. None of these has been proven. The authors are careful to call them possibilities rather than explanations.
The study carries important limitations that temper confidence in its precision. The statistical uncertainty around many of the mediation estimates was substantial enough that researchers could not regard the proportions as reliable. Sensitivity analyses suggested that some estimates involving weight loss may have been distorted by unintentional weight loss in placebo participants due to illness or frailty. Missing data and the frequency of measurements also constrained what the analysis could definitively show. The researchers note that their findings do not establish with certainty that the measured risk factors fully account for the drug's benefit—only that they cannot.
What emerges is a portrait of a drug that works better than the current understanding of cardiovascular disease would predict. Semaglutide is a glucagon-like peptide-1 receptor agonist, a class of medication originally developed for diabetes that has proven effective for weight loss. The cardiovascular benefits in people without diabetes suggest the drug is doing something beyond what weight loss alone would accomplish. The SELECT trial deliberately excluded people with diabetes to isolate the effect in a population where the drug's primary action is weight reduction, yet the protection persists even when accounting for that weight loss and related improvements in traditional risk factors.
The findings point toward a research agenda. Future work will need to measure the biological pathways the current analysis could not capture—examining vascular function, plaque composition, inflammatory markers beyond C-reactive protein, liver and cardiac fat, and the full spectrum of circulating proteins. Until that work is done, clinicians and patients know that semaglutide reduces heart events in this population, but they cannot fully explain why. The drug works. The mechanism remains partially hidden.
Notable Quotes
The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide's cardiovascular protection.— Study authors in the European Heart Journal analysis
Potential mechanisms include effects on inflammation, atherosclerotic plaque biology, steatohepatitis, epicardial fat, and circulating proteins, but these explanations remain speculative.— Study authors
Want the full story?
Read the original at News-Medical ↗